Use of liposomal amphotericin B in critically ill patients: a retrospective, multicenter, clinical study. Journal of chemotherapy (Florence, Italy) [J Chemother] Journal article | | Title | Use of liposomal amphotericin B in critically ill patients: a retrospective, multicenter, clinical study. | | Author(s) | Alvarez-Lerma F, Mariscal F, Quintana E, Rialp G, Diaz-Reganon J, Perez MJ, Alvarez-Sanchez B, Ausin Aoiz I, Study Group of Liposomal Amphotericin B in the Icu | | Institution | Hospital Universitari del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain. Falvarez@imas.imim.es | | Source | J Chemother 2009 Jun; 21(3):330-7. | | Abstract | The clinical use of liposomal amphotericin B in 179 patients admitted to 30 medical-surgical intensive Care Units (ICUs) treated with this agent in 2006 was analyzed. Invasive fungal infections were proven, probable and possible in 44%, 16%, and 25% of cases, respectively. Fungi isolated were Candida albicans (38%), non-albicans Candida spp. (15%) and Aspergillus spp. (7%). The mean duration of treatment was 15 days (mean dose 3.7 mg/kg/day). The drug was used as rescue treatment after fluconazole or caspofungin in 47% of patients and as first line in 52% with a satisfactory clinical response in 54% of cases (72.6% with proven infection). Microbiological eradication was achieved in 68% of cases. Adverse events occurred in 51 patients but were severe in only 4. The use of liposomal amphotericin B both as first line and rescue treatment and mainly for proven invasive fungal infection was associated with a high rate of satisfactory clinical response. | | Language | eng | | Pub Type(s) | Journal Article
Research Support, Non-U.S. Gov't
| | PubMed ID | 19567355 |
|
|
| |
Advertise on this site.
| | |
|
